Acurx Pharmaceuticals Inc... (ACXP)
NasdaqCM: ACXP
· Real-Time Price · USD
1.54
+0.07 (4.76%)
At close: Aug 12, 2026, 3:59 PM
Company Description
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus (MRSA), vancomycin resistant enterococcus (VRE), and drug-resistant streptococcus pneumoniae (DRSP), as well as B. anthracis. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.
Acurx Pharmaceuticals Inc.
| Country | United States |
| IPO Date | Jun 25, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 4 |
| CEO | Mr. David P. Luci CPA, Esq., J.D. |
Contact Details
Address: 259 Liberty Avenue Staten Island, NY United States | |
| Website | https://www.acurxpharma.com |
Stock Details
| Ticker Symbol | ACXP |
| Exchange | NasdaqCM |
| Fiscal Year | Jan '25 - Dec '25 |
| Reporting Currency | USD |
| CIK Code | 0001736243 |
| CUSIP Number | n/a |
| ISIN Number | n/a |
| Employer ID | n/a |
| SIC Code | n/a |
Key Executives
| Name | Position |
|---|---|
| Mr. Robert J. DeLuccia | Co-Founder & Executive Chairman |
| Mr. David P. Luci CPA, Esq., J.D. | Co-Founder, President, CEO, Corporate Secretary & Director |
| Mr. Robert G. Shawah CPA | Co-Founder & CFO |
| Dr. Michael H. Silverman B.Sc., F.A.C.P., FACR, M.B.A., M.D. | Medical Director |